Regulation of cytokine expression in human plasmacytoid dendritic cells by prostaglandin I2 analogues

European Respiratory Journal

Volumn 33, Issue 2, 2009, Pages 405-410

  Hung, C H ^a,b,d   Chu, Y T ^d   Suen, J L ^a,c   Lee, M S ^d   Chang, H W ^d   Lo, Y C ^a   Jong, Y J ^a,b,d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b Dept of Paediatrics   (Taiwan)

^c Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^d All Kaohsiung Medical University Hospital ^*  (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Dendritic cell; Iloprost; Interferon ; Interleukin 10; Prostaglandin; Tumour necrosis factor

Indexed keywords

ALPHA INTERFERON; CAY 10449; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; FORSKOLIN; ILOPROST; IMIQUIMOD; INTERLEUKIN 10; PROSTAGLANDIN DERIVATIVE; PROSTANOID RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNIPROST;

ARTICLE; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IN VITRO STUDY; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CYCLIC AMP; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOPROSTENOL; FORSKOLIN; GENE EXPRESSION REGULATION; HUMANS; ILOPROST; INTERFERON-ALPHA; INTERLEUKIN-10; OLIGONUCLEOTIDES; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59649123455     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00070008     Document Type: Article

References (23)

1. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 2000; 12: 114-121.
2. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
3. Soumelis V, Liu YJ. From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur J Immunol 2006; 36: 2286-2292.
4. Fonteneau JF, Gilliet M, Larsson M, et al. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood 2003; 101: 3520-3526.
5. Curiel TJ, Cheng P, Mottram P, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004; 64: 5535-5538.
6. Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478-6487.
7. de Heer HJ, Hammad H, Soullié T, et al. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004; 200: 89-98.
8. Bratke K, Lommatzsch M, Julius P, et al. Dendritic cell subsets in human bronchoalveolar lavage fluid after segmental allergen challenge. Thorax 2007; 62: 168-175.
9. 2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol 2007; 178: 702-710.
10. Idzko M, Hammad H, van Nimwegen M, et al. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest 2007; 117: 464-472.
11. Guzylack-Piriou L, Balmelli C, McCullough KC, Summerfield A. Type-A CpG oligonucleotides activate exclusively porcine natural interferon-producing cells to secrete interferon-α, tumour necrosis factor-α and interleukin-12. Immunology 2004; 112: 28-37.
12. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74-86.
13. Ito T, Amakawa R, Inaba M, et al. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol 2004; 172: 4253-4259.
14. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2: 151-161.
15. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
16. Helliwell RJ, Adams LF, Mitchell MD. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 101-113.
17. Kunikata T, Yamane H, Segi E, et al. Suppression of allergic inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol 2005; 6: 524-531.
18. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNF-α in pulmonary pathophysiology. Respir Res 2006; 7: 125-133.
19. Aronoff DM, Peres CM, Serezani CH, et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol 2007; 178: 1628-1634.
20. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.
21. Gehlhar K, Bilitewski C, Reinitz-Rademacher K, Rohde G, Bufe A. Impaired virus-induced interferon-α2 release in adult asthmatic patients. Clin Exp Allergy 2006; 36: 331-337.
22. Lee PY, Reeves WH. Type I interferon as a target of treatment in SLE. Endocr Metab Immune Disord Drug Targets 2006; 6: 323-330.
23. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46: 1828-1834.